ClinicalTrials.gg
RecruitingNCT04185272IMMUNOCOLUpdated Oct 1, 2026

Butyrophilins Role in Colon Cancer

An interventional study of analysis of BTN and BTNL status in Colonic Cancer, sponsored by Institut Paoli-Calmettes. Recruiting at 1 site in France. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2026-10-01.

Sponsored by Institut Paoli-Calmettes · Not applicable, Interventional, and Basic science

How we know

From the registry’s dates

  • Started Jun 2020; still recruiting 6 years 4 months later.

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Not applicable
Study type
Interventional
Enrollment
200
Allocation
Non-randomized
Ages
18 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-22

Among 213 studies in Colonic Neoplasms with a site in France — 49 open to participants now, 66 under way, 13 of them phase 3. Colonic Neoplasms · France.

Planned enrollment
66th of 143
200 · median 186
Started
2020
with 10 others
No phase
43 of 213
14 open now
Primary completion
2027-06
later than 32 of 65 live
Registered
134th of 213
by date

Among the 213 studies in Colonic Neoplasms with a site in France, this one is the 66th largest by planned enrollment of the 143 interventional ones that give a count, is one of 11 that started in 2020, is one of 43 with no phase, reaches primary completion later than 32 of the 65 other live ones, and was the 134th registered.

Colonic Neoplasms

2,457 studies on the registry are indexed under Colonic Neoplasms; 456 are open to participants now.

Browse Colonic Neoplasms studies →

Open to participants now

49 of the 213 studies in Colonic Neoplasms with a site in France are open now. Recruiting first, the newest first:

44 more — sign in →

All 49 open studies →

A study can be open while its sites in France have not opened yet or have stopped. Only those recruiting at a site in France →

Who these studies take

Of the 326 Colonic Neoplasms studies recruiting now, 202 (62%) set no upper age limit and 72 (22%) stop at 75 or younger; 19 take children under 18; 35 take healthy volunteers.

This study: 18 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 213 studies in Colonic Neoplasms with a site in France, or all of them as a file.
02

Study summary

quantification of BTNL molecules in colon cancer in order to determinate if their could be used as a prognostic marquer

03

Conditions studied

  • Colonic Cancer

Browse trials for

04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Patient is older than 18 years old,
  • Signed participation consent,
  • Non- colon cancer immediately resectable or metastatic and liver synchronous for which it was decided a combined colic and liver surgery (metastatic patient at the outset) in multidisciplinary consultation meeting.
  • Performance Status (PS) 0 or 1
  • affiliated to the social security or beneficiary

Exclusion criteria

Exclusion Criteria:

  • Rectal cancer, colon cancer recurrence
  • Emergency of colon cancer Surgery
  • History of inflammatory disease of the digestive tract (Crohn's disease or ulcerative colitis)
  • Patient who received therapy other than chemotherapy
  • Patient treated with immune-suppressors or long-course \<12 months
  • Pregnant women or likely to be pregnant (without effective ) or breastfeeding,
  • Person in urgent situation, person under legal protection measure, or unable to express his / her consent,
  • Impossibility of submitting to the medical examination of the test for geographical, social or psychological reasons
Terms in these criteria, in plain language(4)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Metastases

Cancer that has spread from where it began to other parts of the body. “Metastatic” cancer is cancer that has spread this way.

Adjuvant and neoadjuvant

Neoadjuvant treatment is given before the main treatment (usually surgery), often to shrink a tumor. Adjuvant treatment is given after it, to lower the chance of the cancer coming back.

Corticosteroids (steroids)

Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.

Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

05

Study design

Phase
Not applicable
Primary purpose
Basic science
Allocation
Non-randomized
Intervention model
Parallel assignment
Masking
None (open label)
Enrollment
200 participants (estimated)

Study arms

  • Experimental
    non-metastatic colon cancer

    Biological: analysis of BTN and BTNL status

  • Experimental
    metastatic colon cancer

    Biological: analysis of BTN and BTNL status

Interventions

  • Biologicalanalysis of BTN and BTNL status

    analysis of BTN and BTNL expression in colon cancer and hepatic metastasis

06

What researchers measure

Primary outcomes

  1. evaluation of BTNL3, BTNL8 and BTNL9 expression by transcriptomics and immunohistochemistry

    healthy and cancerous colon ad metastasis (if applicable) will be analysed by

    Time frame: 8 years

07

Study locations

1 of 1 sites recruiting
08

References and documents

Individual participant data

Plan to share: No

No publications or documents are linked to this record.

09

Timeline

1 registry update since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Started Jun 2020 (actual). Primary completion is estimated for Jun 2027, 84 months after the start.

Of 382 non-industry interventional studies with no phase under Colonic Neoplasms, half reached primary completion within 31 months of starting (the median), counting those still running; a quarter within 17 and three quarters within 55. This study's planned 84 months is above that.

Counting every sponsor, half of 404 studies reached it within 30 months; a quarter within 16 and three quarters within 51.

How these figures are worked out, and which studies are left out of them.

Registered
Dec 2, 2019
First posted
Dec 4, 2019
StartActual
Jun 30, 2020
Primary completionEst.
Jun 30, 2027
CompletionEst.
Jun 2028
Last update
Oct 1, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
Minor edits
Nothing that changes what the study is or who can join. Edited: identifiers, verification date, oversight details, site details and index terms
1 update, last Oct 1, 2026
Show all 1 update
  1. Oct 1, 2026
    Minor edits only
    + 5 other changes: identifiers, verification date, oversight details, site details and index terms

From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗

10

Registry details

Key details

Study ID
NCT04185272
Responsible party
Sponsor
First posted
Dec 4, 2019
Start date
Jun 30, 2020
Primary completion
Jun 30, 2027 (estimated)
Completion
Jun 2028 (estimated)
Last update
Oct 1, 2026

Study contacts

Jihane PAKRADOUNI, PharmD,PhD
Contact
drci.up@ipc.unicancer.fr
04 91 22 37 78
Laurie-Anne GOUTY, PhD
Contact
drci.up@ipc.unicancer.fr
33491223778

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion